RESI Boston Returns June 16-18: Connect with Top Investors and Life Science Leaders

8 Apr

By Max Braht, Director of Business Development, LSN

Max-Braht-HeadshotLife Science Nation invites you to RESI Boston June, taking place June 16-18 and 23, 2025. The conference kicks off in person at the Westin Copley Place on Monday, June 16, where attendees can take part in face-to-face networking, live investor panels, workshops, and the Innovator’s Pitch Challenge. This will be followed by two days of virtual partnering on June 17-18, 23, allowing participants to continue making valuable connections from anywhere in the world.

The Investor Panels will be held live on June 16 and feature speakers from across the global early-stage investment landscape. Topics include:

Investor Panel Schedule (EDT – June 16)

Time (EDT) Investor Panels
9:00 Beyond Big Pharma
Partnering Early to Foster Innovation
10:00 Aging and Longevity
Investing for Healthier Lifespans
11:00 Health System Partners
Novel Partnering Approaches to Improve Quality of Care
13:00 AI in Healthcare
Investing in the Intersection of Life Sciences and Technology
14:00 Beyond Venture Capital
Funding Opportunities for Early-Stage Companies
15:00 CNS Diseases
Latest Innovations and Investment Trends
16:00 Medical Devices
Latest Trends in Medtech Investments

These panels offer direct insight from investors and strategic partners actively funding early-stage innovation in biotech, medtech, diagnostics, and digital health.

Super Early Bird Discount Ends April 11
Register by April 11 to save $300 on your RESI Boston pass, or bundle with RESI September to save $1,000 on both events. Don’t miss your chance to join the global early-stage community and build your investor network.

Xontogeny’s Garabedian Must-Watch Interview: Getting Discovered, Fundraising, Outlook & More

8 Apr

Sougato-DasThis can’t-miss interview features one of the titans of the early-stage life sci VC world. Chris Garabedian, founder of the Xontogeny fund, fueled by Perceptive Advisors, shares his thoughts on you how to get your company funded, effective entrepreneurship, and what the current US and international political climate could mean for the future of biotech startups. Xontogeny is a regular at RESI conferences and will be one of the flagship investors at RESI Boston June. Focusing on seed, series A and series B, they can invest $0.5M to $20M and facilitate larger check sizes for later stages with their Perceptive Advisors umbrella. Xontogeny is open to working with all types of management teams, including first-time entrepreneurs.

This video spans multiple topics, from the benefits of engaging an experienced, active investor in the seed round, to how to Xontogeny and what Chris would like to see in the initial outreach, as well as how they may be involved in various stages of development. The video concludes by discussing the industry as it now stands, and where Chris thinks it will go, in light of the changes in recent months in the US and international political and economic climate. Chris gave a lot of very valuable advice to early-stage life science companies on how to focus on what will make their fundraise the most successful. Click on this link to view the full interview – thank you, Chris, for your time!

Hot Investor Mandate: Global Pharmaceutical Company Seeks Partnerships with Early-Stage Therapeutics Companies Developing Biologics

8 Apr

A global healthcare company that specializes in plasma-related medicines has a global presence in the US, Europe, and Asia. The firm’s external innovation arm seeks to partner with early-stage companies developing therapeutic assets that strategically align with the firm’s focus areas. The group is science-focused and strategically invests in the corporation’s long-term goal of developing pipelines in biotech beyond plasma-related medicines. The group primarily makes equity investments but is open to different structures such as co-development, licensing, and potentially acquisitions. The group often co-invests/syndicates with other investors and typically does not require a board seat. The group is open to considering global opportunities with a focus on the US and Europe. 

The group is focused on therapeutics and is not interested in diagnostics or other sectors. The group seeks strategic alignments within the parent company’s pharma business, which focuses on immunology, infectious diseases, pulmonology, and hematology. The group is particularly interested in biologics due to their expertise in this class of assets and is open to considering other classes of assets such as small molecules, cell and gene therapy (platform), mRNA therapies, etc. The group is also open to considering orphan diseases as well. In terms of phases of development, the group is interested in pre-clinical to early clinical phases. 

The group does not have any specific requirements for the company’s management team. The group acts as an active investor and is open to working with portfolio companies with their in-house expertise and leveraging the firm’s manufacturing capabilities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: USA-Based Digital Health Fund Looking to Invest in Seed-Stage Startups

8 Apr

A digital healthcare-focused seed fund that was founded in 2015 typically acts as the lead investor in a priced equity round. The firm’s team is made up of three partners and has collectively invested in more than a dozen digital health companies as individual investors. The fund currently focuses on opportunities across the United States, with a target investment in the $500,000 range. 

The firm seeks to fund companies working in the digital health space, including health data management systems, patient-physician interface, cloud computing, and software-enabled devices. 

The firm looks for teams that have some healthcare experience in senior management. The firm prefers a strong founding team, possessing varied skills that include technical expertise, sales, operational and marketing experience in senior leadership. After investment, the firm actively advise portfolio companies in various ways, including helping with introductions to health system customers, building teams and advising on operations and management. As such the firm will usually hold a seat on the board along with the founders. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Japanese Cross-Border VC Firm Invests in Therapeutic Startups Worldwide

8 Apr

A cross-border venture capital firm founded in 2014 and is headquartered in Tokyo, Japan, with USA offices in Cambridge, MA and Seattle, WA is currently investing from their second fund of $95M. Its LPs includes some of the largest Japanese pharmaceutical companies. The firm has also launched a new life sciences incubator through which the firm seeks to nurture and advance early-stage therapeutic concepts and technologies with the goal of bringing them to a more mature stage of development. Typically, the firm makes an initial investment ranging from under $1M to $3-6M dependent on the company’s stage of development. The firm can allocate up to $16M over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide. 

The firm only invests in therapeutics and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area. 

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: UK-Based VC Firm Seeks Investments in Women-Led Health-Tech Startups

8 Apr

A venture capital firm based in the UK and founded in 2020 invests in women-led businesses in biosciences. The firm centers on a USD $100M fund raised as two rounds, the first having $30M to invest. The funds are focused health-tech ventures, with the main goal to hold investors and businesses accountable for diversity in management and teams. Check sizes can range between USD $350k-1.5M. The firm engages with companies in early stages and can also help identify ventures that they can back at a later stage. If the firm decides to not move forward with an investment, they are happy to support and utilize their global network to provide warm introductions to other investors and KOLs they have relationships with. The firm acts as a co-investor and will not lead. The firm is open to meeting companies based in the US, UK, Europe, Australia, and Asia. 

The firm does not invest in therapeutics and direct consumer marketing. The firm is interested in heavy sciences that have a technical element, including medical devices, diagnostics, and digital health. They may look at platforms that help identify therapeutics but will not look at pure therapeutics. The firm is indication-agnostic. The firm would like to see companies with a protectable IP. 

The firm does not require founders to be female, but require female management team members. The firm typically do not sit on board or observer seats but may if a company were to request. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Life Science Nation Presents the RESI Europe 2025 Program Guide 

26 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

In partnership with Biocat, Life Science Nation (LSN) is excited to announce the Program Guide for RESI Europe 2025, hosted at the InterContinental Hotel in Barcelona. The conference will take place on April 1 in person, followed by two virtual partnering days on April 2-3. This hybrid event connects life sciences innovators with global investors and strategic partners.

RESI Europe will feature key conference components, including the Innovator’s Pitch Challenge, where over 44 cutting-edge startups will showcase their technology to a panel of investors. The event also includes investor panel discussions on current trends, industry expert-led interactive workshops, and an exhibitor showcase.

Explore the full program in the guide below and get ready to engage with key players shaping the future of life sciences investment and innovation. Don’t miss this opportunity – there’s still time to register!

(Click to View PDF Version of RES Europe Program Guide)




← Older Entries
Newer Entries →